西藏药业
(600211)
| 流通市值：118.16亿 | | | 总市值：118.16亿 |
| 流通股本：3.22亿 | | | 总股本：3.22亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 712,108,915.5 | 2,806,713,295.85 | 2,175,443,351.59 | 1,614,697,734.98 |
| 营业收入 | 712,108,915.5 | 2,806,713,295.85 | 2,175,443,351.59 | 1,614,697,734.98 |
| 二、营业总成本 | 424,599,500.37 | 1,865,690,789 | 1,408,185,831.63 | 1,028,685,651.52 |
| 营业成本 | 37,344,055.65 | 162,296,561.26 | 110,341,212.94 | 69,504,712.55 |
| 税金及附加 | 7,061,159.67 | 37,095,519.04 | 30,435,075.08 | 23,880,051.16 |
| 销售费用 | 387,363,232.55 | 1,562,404,535.93 | 1,212,500,547 | 907,312,573.4 |
| 管理费用 | 26,174,144.96 | 122,137,403.61 | 79,711,039.37 | 53,532,329.64 |
| 研发费用 | 5,275,211.59 | 28,937,686.41 | 17,025,333.28 | 10,524,929.03 |
| 财务费用 | -38,618,304.05 | -47,180,917.25 | -41,827,376.04 | -36,068,944.26 |
| 其中:利息费用 | -1,854,082.29 | 9,291,711.67 | 9,216,592.02 | 5,257,591.64 |
| 其中:利息收入 | 35,816,485.82 | 59,273,510.36 | 50,652,199.96 | 43,004,334.62 |
| 加:公允价值变动收益 | -1,423,805.47 | -18,985,201.5 | -4,032,722.33 | -4,369,249.51 |
| 加:投资收益 | 5,475,274.24 | 15,103,560.39 | 12,570,708.4 | 7,686,321.45 |
| 资产处置收益 | - | 1,960,495.62 | 2,082,461.73 | 2,076,455.95 |
| 资产减值损失(新) | - | 197,574.52 | -47,985.65 | -48,045.49 |
| 信用减值损失(新) | - | -633,689.04 | -362,337.02 | -362,221.85 |
| 其他收益 | 10,954,646.59 | 221,785,029.88 | 106,985,312.57 | 106,337,005.65 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 302,515,530.49 | 1,160,450,276.72 | 884,452,957.66 | 697,332,349.66 |
| 加:营业外收入 | 120,324.49 | 361,232.67 | 789,520.01 | 649,686.43 |
| 减:营业外支出 | 988,416.37 | 8,727,448.95 | 2,416,036.5 | 2,107,950.36 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 301,647,438.61 | 1,152,084,060.44 | 882,826,441.17 | 695,874,085.73 |
| 减:所得税费用 | 31,398,719.02 | 95,008,864.78 | 87,679,666.16 | 69,790,528.05 |
| 六、净利润 | 270,248,719.59 | 1,057,075,195.66 | 795,146,775.01 | 626,083,557.68 |
| 持续经营净利润 | 270,248,719.59 | 1,057,075,195.66 | 795,146,775.01 | 626,083,557.68 |
| 归属于母公司股东的净利润 | 269,280,367.86 | 1,051,288,308.24 | 791,866,935.56 | 623,136,741.31 |
| 少数股东损益 | 968,351.73 | 5,786,887.42 | 3,279,839.45 | 2,946,816.37 |
| (一)基本每股收益 | 0.84 | 3.26 | 2.46 | 1.93 |
| (二)稀释每股收益 | 0.84 | 3.26 | 2.46 | 1.93 |
| 八、其他综合收益 | -1,616,882.1 | 16,352,053.8 | -12,079,404.53 | 6,723,909.44 |
| 归属于母公司股东的其他综合收益 | -1,616,882.1 | 16,352,053.8 | -12,079,404.53 | 6,723,909.44 |
| 九、综合收益总额 | 268,631,837.49 | 1,073,427,249.46 | 783,073,875.81 | 632,807,467.12 |
| 归属于母公司股东的综合收益总额 | 267,663,485.76 | 1,067,640,362.04 | 779,787,531.03 | 629,860,650.75 |
| 归属于少数股东的综合收益总额 | 968,351.73 | 5,786,887.42 | 3,286,344.78 | 2,946,816.37 |
| 公告日期 | 2025-04-29 | 2025-03-15 | 2024-10-30 | 2024-08-14 |
| 审计意见(境内) | | 标准无保留意见 | | |